RxDoctor Payments Data

Melissa le

Optometrist · Chesapeake, VANPI 1275846503

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,555 of the $6,462 with a category attached, or 86.0%. 23 manufacturers reported payments, led by Alcon at 37.1% of the total. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,462in general payments, 2019–2025

Across 178 payments — averaging $36.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$1K
  • Johnson & Johnson Vision Care, Inc.$1K
  • Sun Pharmaceutical Industries Inc.$286
  • Coopervision Inc.$220
  • Glaukos Corporation$177
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$90714%
  • Food & beverage$5,55586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,462 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$90,555
Medicare patients
461
Services billed
1,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CystadropsCysteamine Hcl13$120,299
RestasisCyclosporine39$42,511
XiidraLifitegrast12$19,440
Cyclosporine25$14,202
MieboPerfluorohexyloctane/Pf12$8,839
Latanoprost67$643
Prednisolone Acetate11$471
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$1,077$42,51139 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$52$28,27824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →